https://www.pharmaradar360.com/article/a97eb6c6b7adfc20PharmaRadar360en2026-04-19T10:04:30.000ZUpdate for Jitendra Narayanhttps://www.pharmaradar360.com/article/07bbfe5feea733eePharmaRadar360en2026-04-19T10:04:30.000ZUpdate for Rishabhhttps://www.pharmaradar360.com/article/ce8456846a2ff1f3PharmaRadar360en2026-04-19T06:14:12.000ZPFA Under Deep Sedation and Non‐Invasive Monitoring in Atrial Fibrillation Patients With Obstructive Sleep Apneahttps://www.pharmaradar360.com/article/8090e7a59c5579dfPharmaRadar360en2026-04-19T06:10:14.000ZMultipoint Pacing Versus Cardiac Resynchronization Therapy in Heart Failure: A Systematic Review and Meta‐Analysishttps://www.pharmaradar360.com/article/0c98088ffca04367PharmaRadar360en2026-04-19T06:03:48.000ZAtrial Reverse Remodeling by Bachmann's Bundle Pacing With Improved Interatrial Dyssynchrony: Case Serieshttps://www.pharmaradar360.com/article/3725f296215d1353PharmaRadar360en2026-04-19T05:59:53.000ZStrength‐Duration Characterisation of Subcutaneous Pacing: A Preclinical Studyhttps://www.pharmaradar360.com/article/393f900566cc70d1PharmaRadar360en2026-04-19T03:45:14.000ZScientists say this type of olive oil could boost brain powerhttps://www.pharmaradar360.com/article/079c310c7c4f9dc6PharmaRadar360en2026-04-19T03:04:33.000Z10x Genomics Unveils Atera Spatial Platform at AACR Meetinghttps://www.pharmaradar360.com/article/162f9b1b107013acPharmaRadar360en2026-04-19T00:25:24.000ZUpdate for Jitendra Narayanhttps://www.pharmaradar360.com/article/e9c0ad7c3b91f7eaPharmaRadar360en2026-04-19T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/27a14b34a9a5974ePharmaRadar360en2026-04-19T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/b4006405bc0a21aaPharmaRadar360en2026-04-19T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/f16f2bcfeb7531cePharmaRadar360en2026-04-19T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/f0e59d5cce475f24PharmaRadar360en2026-04-19T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/eb1e157ea9908edcPharmaRadar360en2026-04-19T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/07f2c5e14da41332PharmaRadar360en2026-04-19T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/c5860d2357c2154ePharmaRadar360en2026-04-19T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/c2d3667800217c46PharmaRadar360en2026-04-19T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/a0aa201cd9077123PharmaRadar360en2026-04-19T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/c72803ab614b86d4PharmaRadar360en2026-04-19T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/7459a66d910cdda8PharmaRadar360en2026-04-19T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/d8265e329e099bdePharmaRadar360en2026-04-19T00:00:00.000Z6203https://www.pharmaradar360.com/article/3fb210180c683c7fPharmaRadar360en2026-04-19T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/b97e70d4c4684c90PharmaRadar360en2026-04-18T23:13:44.000ZThree gene therapy pioneers just won the Breakthrough Prize. This is their storyhttps://www.pharmaradar360.com/article/a075b48f50136515PharmaRadar360en2026-04-18T20:30:00.000ZZelicapavir Demonstrates High Clinical and Functional Barrier Against Antiviral Resistance: Results from a Randomized Double-Blind Placebo-Controlled Pediatric RSV Antiviral Clinical Trialhttps://www.pharmaradar360.com/article/292f40a55c3fcbdaPharmaRadar360en2026-04-18T20:29:00.000ZZelicapavir Decreases Symptom Duration, Hospitalization and Viral Load in a Global, Randomized, Double-Blinded, Placebo-Controlled Phase II Trial of High-Risk Adults with RSVhttps://www.pharmaradar360.com/article/0294d9e731c9c3fdPharmaRadar360en2026-04-18T16:29:00.000ZPotent STAT6 Inhibitor EPS-3903 Has Excellent Preclinical Pharmacokinetics Enabling Sustained STAT6 Inhibition with Once-Daily Oral Dosing in Humanshttps://www.pharmaradar360.com/article/da6d995376702ffcPharmaRadar360en2026-04-18T14:08:55.000ZIt doesn’t matter how much you sit — walking more could lower your risk of death and diseasehttps://www.pharmaradar360.com/article/0a4c993a8c315e0cPharmaRadar360en2026-04-18T13:48:37.000ZUFRJ reúne professores eméritos em articulação permanente por ideias e soluções para a universidadehttps://www.pharmaradar360.com/article/6ba122f96e0e47d7PharmaRadar360en2026-04-18T13:05:40.000ZLive Updates From the AACR Annual Meeting 2026: Saturday, April 18